Natco Pharma Ltd.

Natco Pharma is currently trading at Rs. 573.95, up by 16.00 points or 2.87% from its previous closing of Rs. 557.95 on the BSE.

The scrip opened at Rs. 564.00 and has touched a high and low of Rs. 584.00 and Rs. 538.50 respectively. So far 22,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 640.00 on 30-Jul-2013 and a 52 week low of Rs. 340.00 on 03-Aug-2012.

Last one week high and low of the scrip stood at Rs. 640.00 and Rs. 488.35 respectively. The current market cap of the company is Rs. 1,800.00 crore.

The promoters holding in the company stood at 56.63% while Institutions and Non-Institutions held 20.81% and 22.57% respectively.

US Court of Appeals for the Federal Circuit has given a ruling in Natco Pharma’s favour by allowing it to launch a copycat version of Copaxone through its marketing partner Mylan Inc during May 2014. Copaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis. The product is estimated to have clocked revenues, in USA, of about $ 3.45 billion during 2012.

Earlier this month, the company received marketing approval for its Rizatriptan Benzoate (Maxalt-MLD) orally disintegrating tablets, 5 mg and 10 mg (base) from US Food & Drug Administration (USFDA).

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.